Effect of Metformin vs Placebo on Weight and Metabolic Factors in NCIC CTG MA.32

BACKGROUND: Metformin may improve metabolic factors (insulin, glucose, leptin, highly sensitive C-reactive protein [hs-CRP]) associated with poor breast cancer outcomes. The NCIC Clinical Trials Group (NCIC CTG) MA.32 investigates effects of metformin vs placebo on invasive disease-free survival and...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Natl Cancer Inst
Auteurs principaux: Goodwin, Pamela J., Parulekar, Wendy R., Gelmon, Karen A., Shepherd, Lois E., Ligibel, Jennifer A., Hershman, Dawn L., Rastogi, Priya, Mayer, Ingrid A., Hobday, Timothy J., Lemieux, Julie, Thompson, Alastair M., Pritchard, Kathleen I., Whelan, Timothy J., Mukherjee, Som D., Chalchal, Haji I., Oja, Conrad D., Tonkin, Katia S., Bernstein, Vanessa, Chen, Bingshu E., Stambolic, Vuk
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2015
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4565534/
https://ncbi.nlm.nih.gov/pubmed/25740979
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djv006
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires